You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Inflammatory Diseases
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Login
Username:

Password:


Related Headlines

Immunic granted European patent for vidofludimus calcium dosing regimens

Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment

Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis

Kelun-Biotech and Harbour BioMed receive China IND approval for atopic dermatitis therapy

Melodia Therapeutics reports award of US patent covering MLD-151

GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline

Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH

Formosa Pharmaceuticals signs licensing deal with Arrotex for APP13007 in Australia and New Zealand

Merck and Mayo Clinic launch AI-driven drug discovery collaboration

Palisade Bio makes Clinical Advisory Board appointment

STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)

Hoth Therapeutics granted US patent for novel exon-skipping therapy targeting allergic diseases

DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval

Devonian reports gene expression data showing Thykamine's molecular effects in MASH model

Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026